Business Daily Media

Men's Weekly

.

Immuno Cure BioTech acquires Shanghai Teresa Healthcare

Integrating Electroporation Technology & DNA Vaccine Platforms

HONG KONG SAR - Media OutReach - 20 September 2022 - Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation technology and device in China.

The transaction will be settled in cash and shares. Teresa's shareholders will swap for about 1.5% equity in Immuno Cure while the inventor of Teresa's EP technology, Professor XU Yuhong (徐宇虹), maintains her 7.4% direct equity in Teresa.

Teresa EP device delivers brief electrical pulses to promote efficient penetration of DNA vaccine through cell membrane for the enhancement of gene expression and ultimate immune responses. It is the only such device approved by National Medical Products Administration for the administration of DNA vaccine in China. Such EP technology has been an integral part of Immuno Cure's DNA vaccine delivery strategy from research to clinical stage.

Founded in 2004, Shanghai Teresa is an innovative medical device group focusing in electro immunotherapies and rehabilitation therapies. In 2005, Teresa's electroporation technology was developed to enhance the delivery of DNA medicine, based on the intellectual property generated by Shanghai Jiao Tong University under the National 863 Project. Such EP technology has been proven safe and efficacious after deployment of over 10,000 times in collaboration with more than thirty hospitals for the administration of DNA medicine in numerous human trial subjects.

Immuno Cure has two PD-1-Enhanced DNA vaccines currently in phase 1 clinical trial for prevention of COVID-19 and therapeutic cure of HIV/AIDS.

Dr JIN Xia, CEO of Immuno Cure said, "Immuno Cure has partnered with Teresa over the years in developing customised EP delivery strategy for our PD-1-Enhanced DNA vaccines, which has brought about encouraging results in clinical setting recently. I am pleased with this convergence with Teresa, which will no doubt bring our teams even closer together. Teresa will continue to operate independently while leveraging on Immuno Cure's R&D platform for the development of their next generation non-invasive EP technology for intradermal delivery strategy. Immuno Cure is committed to support the continual growth and success of Teresa."

Ms. CHEN Liye, CEO of Teresa said, "Founded on our long term collaboration, Teresa is excited to become a member of Immuno Cure Group. This move will not only provide us with a much closer R&D relationship, which is essential for our technology advancement but also offer us the financial capability to meet future needs. Teresa treasures our collaborations with other players in the field and look forward to continuing our collaborations with new and sustainable EP technology."

Professor CHEN Zhiwei, Director of AIDS Institute at the University of Hong Kong and the Principal Scientific Advisor of Immuno Cure said, "Our research and development work at the AIDS Institute and Immuno Cure has benefitted from Teresa's EP technology and their diligent collaborative effort over the past 12 years. I am pleased to see their relationship developing into an even closer tie. Look forward to the development of the next generation of EP technology for further optimisation of delivery strategy and patient experience."

Dr Percy CHENG, Chairman of Immuno Cure concludes, "This transaction offers Immuno Cure the opportunity to secure Teresa's EP technology for support of not only R&D but also the clinical administration of our PD-1-Enhanced DNA vaccines. We are pleased with Professor XU's decision to remain as our co-investor in Teresa and are optimistic in the future of EP technology in our DNA vaccine development."Hashtag: #ImmunoCureBiotech

The issuer is solely responsible for the content of this announcement.

Immuno Cure BioTech

Immuno Cure BioTech is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of vaccines and immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA vaccine and Anti-Δ42PD1 Blocking Antibody technology platforms.

To learn more about Immuno Cure BioTech, please visit

Shanghai Teresa Healthcare

Founded in 2004, Shanghai Teresa is an innovative medical device group based in Shanghai Zhangjiang Hi-Tech Park, focusing in electro immunotherapies and rehabilitation therapies.

To learn more about Shanghai Teresa Healthcare, please visit




News from Asia

FGA Trust Showcases Hong Kong’s Institutional Strength at 2025 Inclusion Conference on the Bund

HONG KONG SAR - Media OutReach Newswire - 12 September 2025 - FGA Trust, a licensed trustee in Hong Kong, participated in the 2025 Inclusion Conference on the Bund by the invitation of InvestHK, a...

Appier Drives GenAI-Powered Creatives Transformation with AdCreative.ai, Empowering Hong Kong Brands to Accelerate into the Agentic AI Marketing Era

HONG KONG SAR - Media OutReach Newswire - 12 September 2025 - Appier (TSE: 4180), an AI-native SaaS company specializing in AdTech and MarTech solutions, today hosted the GenAI for Marketing Asia ...

Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®

Zhangqiu District, Jinan City, Shandong Province – September 2025HONG KONG SAR - EQS Newswire – 12 September 2025 - Uni-Bio Science Group ("the Group") is pleased to announce the signing of a strat...

10th Belt & Road Summit celebrates decade of business, investment and co-operation achievements

HONG KONG SAR - Media OutReach Newswire - 12 September 2025 - The 10th edition of the Belt and Road Summit in Hong Kong (September 10-11) gathered about 6 200 high-profile participants from govern...

Digital Entertainment Leadership Forum 2025 Kicks Off Today

AI-Driven Innovation Unlocks the Missing Piece in Digital EntertainmentHONG KONG SAR - Media OutReach Newswire - 12 September 2025 - The Digital Entertainment Leadership Forum 2025 (DELF 2025), Cy...

COOFANDY, EKOUAER, and Zeagoo Announce Participation in Oktoberfest 2025 with Joint Pop-Up Event at Substanz Club

MUNICH, GERMANY - Media OutReach Newswire - 13 September 2025 - COOFANDY, EKOUAER, and Zeagoo are excited to announce their participation in the 2025 Munich Oktoberfest, alongside a special off...

Coastline Wealth Management’s Garrett Taylor Named a Top New York Best-in-State Wealth Advisor

LONG ISLAND, US - Media OutReach Newswire - 13 September 2025 - Garrett Taylor, CRPC®, Founder and Managing Partner of Coastline Wealth Management, has earned a place on Forbes' 2025 Best-in-State...

China Telecom Global Showcases at the 10th Belt and Road Summit, Paving the Way for a Smarter Silk Road Future

HONG KONG SAR - Media OutReach Newswire - 13 September 2025 - The 10th Belt and Road Summit was successfully held at the Hong Kong Convention and Exhibition Centre from September 10 to 11, 2025...

IVD Medical Holding Limited and ETHK Group Establish Joint Venture, On-Chain Financial Strategy Upgraded On September 14

NEW YORK, US - Media OutReach Newswire - 14 September 2025 - IVD Medical Holding Limited (01931.HK) released an announcement stating its collaboration with ETHK Group, a global on-chain financial ...

IVD Medical Holding Limited Releases "ETHK" Ecosystem Vision: Technology for the Public, Chain for the Way On September 14

NEW YORK, US - Media OutReach Newswire - 14 September 2025 - IVD Medical Holding Limited (01931.HK) officially announced its name change. Its English name was changed to "ETHK Labs Inc...

AWS research shows strong AI adoption momentum in Australia, with startups outpacing large enterprises in innovation

Amazon Web Services (AWS), an Amazon.com company, released new research revealing that while artificial intelligence (AI) adoption continues to acce...

Changing the World One Bite At a Time: IKU Turns 40

One of Australia’s first plant-based, chef-led eateries and now ready meal provider IKU is celebrating its 40 year anniversary with the business e...

Three generations marking 45 years in hot-air balloons

Australia’s leading hot-air balloon company is celebrating 45 years in the sky and its 700,000th passenger, driven by the passion of father-son du...

Workplace DMs, Reinvented: Deputy Messaging, Purpose-Built For Shift-Based Teams

Deputy, the global people platform for shift-based businesses, has launched Deputy Messaging, a fully integrated, real-time communication tool designe...

Revolutionizing Fulfillment: How Virtual Warehousing is Changing the Game?

The e-commerce landscape is evolving more rapidly than ever, and the way businesses are managing their fulfillment is also revolutionizing. At the...

SME lender Dynamoney welcomes new CEO, Brett Thomas

Strengthens growth ambitions and signals expanded offering Dynamoney, a leading commercial finance provider for Australian SMEs,  has today appoint...

Sell by LayBy